Amphastar Pharmaceuticals, Inc. (AMPH): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Amphastar Pharmaceuticals, Inc. (AMPH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Amphastar Pharmaceuticals, Inc._July 9, 2026 0001297184 false 0001297184 2026-07-09 2026-07-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of
How this was made
The 30-second read
Why it matters
The filing adds a new independent Class III director and specifies cash and equity compensation, but does not disclose changes to management, strategy, financial guidance, or material transactions.
Market read
Primarily governance and director compensation disclosure, with likely limited immediate trading impact.
What to watch
Traders may overreact to director compensation details; without committee assignments, mandates, or strategic initiatives, the incremental information is small.
Background
This is an SEC Form 8-K Item 5.02 governance filing describing a director appointment and related compensation/indemnification terms.
Ticker impact
Amphastar’s board increased director count to 11 and appointed Anthony Pierce as a Class III director with $55,000 cash and $300,000 equity grant value.
Limited, likely short-lived impact unless paired with other operational or strategic disclosures.
The 8-K discloses governance/compensation details for a newly appointed director, with no stated operational change, guidance, or transaction.
Market effects
Minimal sector read-through; this is a corporate governance and director compensation disclosure.
No clear regional market linkage beyond Nasdaq-listed issuer sentiment.
No global catalyst indicated.
Counterpoint
If the director appointment is part of a broader strategic refresh, the market may later re-rate governance quality, but this filing alone does not provide that linkage.
Key entities
- issuerAmphastar Pharmaceuticals, Inc.
Nasdaq-listed company filing the 8-K; board approved an increase in authorized directors and appointed Anthony Pierce.
- directorAnthony Pierce
Appointed Class III director effective immediately, serving until the 2028 annual meeting; receives cash retainer and equity grant.
- officerWilliam J. Peters
CFO, Executive Vice President and Treasurer, signing the 8-K.
